Comprehensive Report on Reproxalap (DB16688)

1. Executive Summary

Reproxalap (DrugBank ID: DB16688), also known by its developmental codes ADX-102 and NS-2, is an investigational, first-in-class, small-molecule modulator of Reactive Aldehyde Species (RASP) developed by Aldeyra Therapeutics.[1] Its novel mechanism involves sequestering RASP, which are pro-inflammatory aldehydes elevated in various ocular and systemic inflammatory conditions, thereby acting upstream in the inflammatory cascade.[5] Reproxalap has been investigated across multiple therapeutic indications, primarily focusing on ocular inflammation. Key indications include dry eye disease (DED) and allergic conjunctivitis (AC), where it is in late-stage development.[2] Development for noninfectious anterior uveitis (NAU) was discontinued following a Phase 3 trial failure.[12] Reproxalap has also been studied for the rare genetic disorder Sjögren-Larsson syndrome (SLS), specifically targeting the associated ichthyosis, and holds U.S. Food and Drug Administration (FDA) Orphan Drug Designation (ODD) for this condition (under the designation for congenital ichthyosis).[1]

The clinical development program for DED has faced significant regulatory challenges. Despite demonstrating efficacy in reducing ocular redness (a sign) and ocular discomfort (a symptom) in controlled dry eye chamber studies, including a recent Phase 3 trial achieving its primary endpoint for discomfort [2], reproxalap has received two Complete Response Letters (CRLs) from the FDA (November 2023 and April 2025).[11] The CRLs cited a failure to demonstrate efficacy in treating ocular symptoms in adequate and well-controlled studies, potentially referencing difficulties in meeting symptom endpoints in field trials and methodological concerns in one submitted chamber study.[11] Aldeyra plans to resubmit the New Drug Application (NDA) in mid-2025, pending results from ongoing DED trials and further FDA discussions.[2] In contrast, clinical development in AC has yielded consistently positive Phase 3 results in allergen challenge models.[9]

Across extensive clinical evaluation involving over 2,900 patients, reproxalap has demonstrated a generally favorable safety and tolerability profile.[2] The most commonly reported adverse event is mild and transient instillation site irritation or discomfort, with no significant safety signals or treatment-related discontinuations highlighted in recent trials or FDA reviews.[2]

2. Introduction

Reproxalap (DrugBank ID: DB16688) is a novel small molecule developed by Aldeyra Therapeutics, identified by developmental codes ADX-102 and NS-2.[1] It represents a first-in-class therapeutic approach targeting Reactive Aldehyde Species (RASP), a group of endogenous, pro-inflammatory molecules.[2]

The therapeutic rationale for reproxalap stems from the understanding that RASP, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), are significantly elevated in various inflammatory conditions, including ocular surface diseases like dry eye disease (DED) and allergic conjunctivitis (AC), as well as systemic disorders.[5] These aldehydes act as upstream mediators in the inflammatory cascade. By covalently binding to cellular components, they can trigger or amplify inflammatory pathways, including the activation of NF-κB and inflammasomes, leading to cytokine release and subsequent tissue inflammation.[6] In DED, RASP are implicated not only in inflammation but also potentially in diminishing tear production and altering tear lipid composition.[27] By sequestering these reactive aldehydes, reproxalap aims to modulate the inflammatory response at an early stage, potentially offering a distinct mechanism compared to existing therapies that typically target downstream mediators like cytokines or histamine receptors.[6] This systems-based approach targets a family of molecules involved in numerous inflammatory pathways.[29]

This report provides a comprehensive overview of reproxalap, synthesizing available information on its chemical profile, mechanism of action, preclinical findings, clinical development program across its primary indications (DED, AC, noninfectious anterior uveitis, and Sjögren-Larsson syndrome), integrated safety profile, and current regulatory status and outlook, based on the provided research materials.

3. Drug Profile and Mechanism of Action

3.1. Chemical Properties

Reproxalap is classified as a small molecule drug.[1] Its chemical name is 2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol.[1] It is also widely known by its synonyms and developmental codes: ADX-102, ADX 102, ADX102, ALD-102, NS-2, NS 2, and NS2.[1] The Chemical Abstracts Service (CAS) Registry Number for reproxalap is 916056-79-6.[1] Its molecular formula is C12​H13​ClN2​O, with an average molecular weight of 236.7 g/mol.[1]

Reproxalap has been formulated primarily as a topical ophthalmic solution for ocular indications, tested at concentrations of 0.1%, 0.25%, and 0.5%.[7] Both standard and novel ophthalmic formulations have been evaluated in clinical trials.[33] For the treatment of ichthyosis associated with Sjögren-Larsson syndrome (SLS), a 1% topical dermal cream formulation has been used.[38] Reproxalap exhibits solubility in DMSO (100 mg/mL with ultrasonic assistance) and has a reported water solubility of 0.237 mg/mL.[1]

Table 1: Reproxalap Key Identifiers

Identifier	Value	Source(s)
Generic Name	Reproxalap	1
DrugBank ID	DB16688	1
Developmental Codes	ADX-102, NS-2	1
CAS Number	916056-79-6	1
Type	Small Molecule	1
Molecular Formula	C12​H13​ClN2​O	1
Molecular Weight	236.7 g/mol (Average)	1
Chemical Name	2-(3-amino-6-chloroquinolin-2-yl)propan-2-ol	1
Developer	Aldeyra Therapeutics	1

This table provides a consolidated summary of the fundamental identifiers for Reproxalap, essential for tracking and referencing the compound across different databases and literature. It aggregates key information found across several sources.[1]

3.2. Pharmacology: Mechanism of Action (MoA)

The primary mechanism of action of reproxalap is the inhibition, sequestration, modulation, or trapping of Reactive Aldehyde Species (RASP).[1] It achieves this by covalently binding to RASP, including key inflammatory mediators like malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE).[10]

RASP are recognized as upstream initiators and amplifiers of inflammation.[6] They are elevated in various ocular and systemic inflammatory diseases and exert their pro-inflammatory effects by modifying cellular components, leading to the activation of downstream signaling pathways such as NF-κB and inflammasomes, ultimately resulting in cytokine release.[8] Reproxalap's action of sequestering RASP occurs early in this cascade, before the significant release of cytokines and the recruitment of inflammatory cells.[6] This upstream intervention represents a novel pharmacological strategy, distinct from conventional anti-inflammatory agents like NSAIDs, corticosteroids, or immunomodulators, which typically target mediators further down the inflammatory pathway.[10] By reducing the overall aldehyde load, reproxalap aims to dampen the inflammatory response more broadly and potentially prevent the perpetuation of inflammation.[10]

Commercial vendor data also suggests reproxalap may reduce PKCα activity and block caspase 3/7 activation in vitro.[25] While these findings align with anti-inflammatory and cell-protective effects, they originate from non-peer-reviewed sources and may require independent validation to confirm their contribution to the overall mechanism.

3.3. Pharmacokinetics (PK) and Pharmacodynamics (PD)

Detailed pharmacokinetic information (absorption, distribution, metabolism, excretion) for reproxalap is limited in the publicly available sources reviewed. DrugBank explicitly states that metabolism and route of elimination data are "Not Available".[1] While preclinical studies were conducted, specific PK parameters or distribution studies were not detailed in the provided materials.[20] The lack of accessible, detailed PK data represents a gap in the public understanding of the drug's disposition, although such information is likely contained within regulatory filings.

Pharmacodynamic activity is primarily inferred from its mechanism of action and clinical efficacy results. The intended PD effect is the reduction of RASP levels in target tissues. Evidence supporting this was observed in a Phase 2a DED trial, where topical ocular reproxalap administration led to a statistically significant reduction in tear MDA levels after 28 days of treatment (p=0.009), providing in vivo confirmation of target engagement in humans.[27] Furthermore, the consistent clinical effects observed across trials, such as the reduction of ocular redness (a sign of inflammation) and ocular discomfort/itching (symptoms) in DED and AC studies, serve as functional evidence of reproxalap's pharmacodynamic activity.[2]

4. Preclinical Development

4.1. Pharmacology

Preclinical studies have provided foundational support for reproxalap's RASP-sequestering mechanism and its potential anti-inflammatory effects. In vitro and preclinical models demonstrated reproxalap's ability to effectively trap free aldehydes.[9] This aldehyde trapping capability translated into observed anti-inflammatory activity, including diminished inflammation, reduced healing time, protection of cellular components from aldehyde-induced damage, and a lowered potential for scarring or fibrosis in various preclinical models.[15] Studies in animal models indicated inhibition of both Th1- and Th2-mediated inflammation.[27] Specific in vitro experiments showed that reproxalap could protect fatty aldehyde dehydrogenase (FALDH)-deficient cells (FAA-K1A, a model relevant to SLS) from the cytotoxicity induced by C18:0-al, a fatty aldehyde.[25] Additionally, reproxalap demonstrated pain-relieving effects by reducing nociceptive behavior in mouse models of carrageenan- and CFA-induced pain.[24]

These preclinical findings consistently supported the hypothesis that RASP sequestration by reproxalap could be a viable therapeutic strategy for various inflammatory conditions, providing the rationale for its progression into clinical trials for ocular inflammation and SLS. However, the available snippets do not detail specific RASP binding affinities, kinetics, or comprehensive mechanism-of-action studies beyond the general aldehyde-trapping effect.[25]

4.2. Toxicology

Reproxalap underwent various toxicity studies in animals as part of its preclinical development program.[15] Based on these studies, the compound appeared to be generally safe and well-tolerated.[15] However, specific details regarding these toxicology studies, such as the species tested, dose levels, duration of exposure, target organs of toxicity (if any), or no-observed-adverse-effect levels (NOAELs), are not provided in the reviewed documents.[20] The general statement of preclinical safety aligns with the tolerability observed in subsequent human clinical trials, but a comprehensive toxicological risk assessment cannot be made from the available information.

5. Clinical Development and Efficacy

5.1. Overview

Reproxalap has been extensively studied in humans, with cumulative exposure exceeding 2,900 patients across numerous clinical trials, primarily focusing on ocular inflammatory conditions and the rare disease Sjögren-Larsson Syndrome.[2] The clinical program has progressed through Phase 3 trials for dry eye disease (DED), allergic conjunctivitis (AC), noninfectious anterior uveitis (NAU), and SLS.

5.2. Dry Eye Disease (DED)

Rationale: DED is a multifactorial disease characterized by inflammation and tear film instability. RASP are implicated in driving ocular inflammation and potentially altering tear film components in DED patients.[10] Reproxalap, by sequestering RASP, was hypothesized to reduce inflammation and improve both signs and symptoms of DED.[27]

Key Trials: The DED program included multiple Phase 2 and Phase 3 trials. Notable studies include a Phase 2a trial (NCT03162783) evaluating different formulations [27], a Phase 2b trial (ADX-102-DED-009 / NCT03404115) [10], the Phase 3 RENEW trial (ADX-102-DED-012 / NCT03879863) [32], the TRANQUILITY trials [8], and several dry eye chamber trials (e.g., NCT03916042, NCT04971031, NCT05102409 mentioned in [58]; a positive Phase 3 chamber trial reported May 2025 [2]). Two trials, a field study and another chamber study, are currently ongoing with results expected in Q2 2025.[11]

Efficacy Results:

• Signs: Reproxalap demonstrated statistically significant reductions in ocular redness, an objective sign of DED accepted by the FDA, in controlled dry eye chamber settings.[8] Improvements in Schirmer's test scores (tear volume) were also noted in Phase 2 trials.[27] A post-hoc analysis of a 12-month safety trial suggested a potential improvement in distance visual acuity compared to vehicle (p=0.018), a finding highlighted as potentially unique for a topical DED therapy.[21]
• Symptoms: Early phase trials showed improvements in patient-reported symptoms like ocular discomfort and dryness.[10] A recently completed Phase 3 dry eye chamber trial successfully met its primary endpoint, demonstrating statistically significant superiority of reproxalap (0.25%) over vehicle in reducing ocular discomfort scores (p=0.002) during a specific post-chamber entry period.[2] However, demonstrating consistent and statistically significant symptom improvement in field trials, which reflect real-world environmental exposure, has proven challenging. A recently completed field trial, while numerically supportive and consistent with prior field trials, did not achieve statistical significance for its primary symptom endpoint.[2]

Regulatory Challenges & Implications: The discrepancy between results from controlled chamber studies and real-world field trials lies at the heart of reproxalap's regulatory difficulties in DED. Chamber studies, while useful for demonstrating rapid onset and effects on signs like redness under controlled stress [2], may not fully capture the chronic, fluctuating nature of DED symptoms experienced by patients daily. Field trials, conversely, are subject to greater variability and often exhibit substantial placebo responses, making it statistically challenging to demonstrate superiority for symptom endpoints.[2] The FDA's two CRLs specifically highlighted the lack of convincing symptom efficacy data from adequate and well-controlled studies, likely reflecting the unmet bar in field trials or concerns about the generalizability of chamber symptom data.[11] The agency also noted potential methodological issues, such as baseline imbalances in a submitted chamber trial, which could confound interpretation.[11] Aldeyra believes the most recent positive chamber trial, which reportedly had balanced baselines, addresses this specific concern.[2] However, ultimate approval likely hinges on generating robust and statistically significant symptom data, potentially from the ongoing field trial or further studies, that meets the FDA's threshold for demonstrating clinical benefit in this challenging indication.

5.3. Allergic Conjunctivitis (AC)

Rationale: RASP are known mediators in the allergic cascade, contributing to inflammation and symptoms like itching and redness.[9] Reproxalap's RASP inhibition offers a novel mechanism to address AC.

Key Trials: The AC program included a Phase 2 trial (NCT03709121) [7], the Phase 3 ALLEVIATE trial (NCT03494504) [7], and the Phase 3 INVIGORATE/INVIGORATE-2 trials (NCT04207736).[8] These trials primarily utilized controlled allergen challenge models (conjunctival allergen challenge or allergen chamber).

Efficacy Results: Reproxalap consistently demonstrated statistically significant and clinically relevant efficacy in Phase 3 trials for AC. Both 0.25% and 0.5% concentrations significantly reduced ocular itching (the primary endpoint in ALLEVIATE and INVIGORATE) compared to vehicle following allergen challenge (p<0.001 to p=0.003 for primary endpoints).[7] Significant improvements were also observed for the key secondary endpoint of responder analysis (≥2-point improvement in itching) and for ocular redness.[9] The drug showed rapid onset of action, with efficacy evident within minutes, and demonstrated both prophylactic and treatment activity (effective when administered before or during allergen exposure).[49] While both doses were effective, the 0.5% concentration was associated with slightly more transient instillation site irritation without providing additional efficacy benefit over the 0.25% dose.[7]

The consistent positive outcomes in multiple Phase 3 AC trials, utilizing controlled allergen challenge models, suggest a stronger case for efficacy in this indication compared to DED. These controlled environments likely facilitate the demonstration of drug effect over placebo, leading to statistically robust results for key symptoms like itching. This positions AC as a potentially more straightforward path to regulatory approval for reproxalap.

5.4. Noninfectious Anterior Uveitis (NAU)

Rationale: NAU is a serious inflammatory condition often requiring corticosteroids. RASP are implicated in the underlying autoimmune inflammation.[35] Reproxalap was investigated as a potential non-steroidal, anti-inflammatory treatment option.[7]

Key Trials: A Phase 2 trial compared reproxalap (0.5% monotherapy and combination with low-dose steroid) to standard-dose prednisolone.[35] This was followed by the Phase 3 SOLACE trial comparing reproxalap to vehicle.[12]

Efficacy Results: The Phase 2 trial suggested promising activity, demonstrating non-inferiority of reproxalap monotherapy (0.5%) to prednisolone monotherapy in reducing anterior chamber inflammatory cell count after 4 weeks (p=0.048 for non-inferiority).[35] Notably, reproxalap did not cause the intraocular pressure (IOP) elevation observed with prednisolone.[7] However, the subsequent Phase 3 SOLACE trial failed to meet its primary and secondary endpoints.[12] While the company reported that reproxalap activity was consistently greater than vehicle, statistical significance was not achieved, reportedly due to unexpectedly high rates of disease resolution in the vehicle group.[12] Specific efficacy data from SOLACE were not provided in the available documents.[13]

Status: Following the negative Phase 3 results, Aldeyra announced the discontinuation of the NAU program for reproxalap in June 2019.[12] The failure underscores the challenges in developing treatments for NAU, where potent standard-of-care therapies exist and disease course can be variable, potentially leading to high placebo/vehicle response rates that obscure drug effects.

5.5. Sjögren-Larsson Syndrome (SLS) / Congenital Ichthyosis

Rationale: SLS is a rare genetic disorder caused by deficient activity of fatty aldehyde dehydrogenase (FALDH), leading to the accumulation of toxic fatty aldehydes.[16] This accumulation contributes to the characteristic symptoms, including severe ichthyosis (dry, scaly, thickened skin).[16] Reproxalap, as an aldehyde trap, offers a mechanism-based approach to sequester these toxic aldehydes and potentially alleviate symptoms, particularly the ichthyosis.[16]

Key Trials: A randomized, double-blind, vehicle-controlled Phase 2 trial evaluated 1% topical dermal reproxalap (NS2) in 12 SLS patients over two months.[16] A subsequent Phase 3 trial, known as the RESET trial (NCT03445650), was initiated.[38]

Efficacy Results: The Phase 2 trial yielded positive results. Central review showed that 5 out of 6 (83%) reproxalap-treated subjects achieved an investigator global assessment rating of "almost clear" or "mild" ichthyosis, compared to none in the vehicle group.[40] All 6 reproxalap-treated subjects showed improvement from baseline (p<0.05), which was statistically superior to the improvement seen with vehicle (p<0.05).[40] The effect appeared to increase over time, with greater reductions in ichthyosis severity observed at 8 weeks compared to 4 weeks, suggesting a potential disease-modifying effect.[40] Changes in dermal biomarkers, including a reduction in elevated skin cholesterol levels, were consistent with drug activity.[46] The Phase 3 RESET trial (NCT03445650) is listed as completed, having enrolled 11 participants.[38] However, specific results or publications from this Phase 3 trial were not found in the provided documents.[2]

Status & Orphan Designation: Reproxalap received FDA Orphan Drug Designation (ODD) for the treatment of congenital ichthyosis (which includes SLS) on April 20, 2017.[16] The designation number is 530116.[17] Despite the positive Phase 2 data and ODD, the lack of accessible Phase 3 results for topical reproxalap in the provided materials raises questions about its current development status for SLS. Notably, Aldeyra is actively developing ADX-629, an oral RASP modulator, for SLS, with a Phase 2 trial pediatric cohort expected to report results in 2025.[62] This parallel development might indicate a strategic shift towards a systemic therapy for this multi-system genetic disorder, potentially deprioritizing the topical reproxalap formulation for SLS.

6. Safety and Tolerability

6.1. Integrated Safety Summary

Reproxalap has been administered to a large patient population, exceeding 2,900 individuals across numerous clinical trials investigating various indications and formulations.[2] Across this extensive clinical experience, reproxalap has consistently demonstrated a favorable safety and tolerability profile.[2]

6.2. Common Adverse Events (AEs)

The most frequently reported adverse event associated with topical ocular administration of reproxalap is mild and transient instillation site irritation or discomfort.[2] This effect is noted to be consistent with the experience with other topical ophthalmic medications.[21] In comparative studies, while present, this irritation appeared less problematic than with lifitegrast.[37]

6.3. Serious Adverse Events (SAEs) and Discontinuations

Treatment-related serious adverse events have generally not been observed in reproxalap clinical trials.[21] Recent Phase 3 DED trials reported no safety signals or treatment-related discontinuations.[2] A 12-month safety trial in DED patients confirmed this profile, showing no treatment-related SAEs and similar ocular safety event rates (covering visual acuity, IOP, slit-lamp exams, and fundoscopy) between reproxalap and vehicle groups.[21] Importantly, even when the FDA issued CRLs for reproxalap in DED due to efficacy concerns, no manufacturing or safety issues were identified by the agency.[4]

6.4. Specific Safety Comparisons

Direct comparisons have provided additional context for reproxalap's safety profile. In a head-to-head, single-dose crossover trial comparing the ocular experience of reproxalap (two formulations) versus lifitegrast 5% in DED patients, reproxalap demonstrated superior comfort over the hour following instillation.[37] Reproxalap scored significantly better regarding ocular discomfort, blurry vision, and dysgeusia – the most common side effects associated with lifitegrast.[37] In the Phase 2 NAU trial, reproxalap monotherapy did not lead to clinically significant elevations in IOP, a known risk associated with the comparator, topical corticosteroid (prednisolone).[7]

Table 3: Summary of Reproxalap Safety Findings

Indication	Key Trials	Patient Exposure (Approx. N)	Most Common AE(s)	SAEs / Discontinuations	Key Safety Comparisons	Snippet IDs
Overall	Multiple Phase 1-3	>2,900	Mild, transient instillation site irritation/discomfort	No significant safety signals; No treatment-related SAEs generally reported; Low discontinuation rates	Generally well-tolerated	2
Dry Eye Disease (DED)	Phase 2a, 2b, 3 (RENEW, TRANQUILITY, Chamber, 12-Month Safety)	>2,500 (across program)	Mild, transient instillation site irritation/discomfort	No treatment-related SAEs in 12-month trial; No treatment-related discontinuations in recent trials; Ocular safety parameters similar to vehicle over 12 months	Superior ocular comfort profile vs. lifitegrast (1-hr post-dose); Similar ocular safety events vs. vehicle (12 months)	2
Allergic Conjunctivitis (AC)	Phase 2, Phase 3 (ALLEVIATE, INVIGORATE)	>625 (Meta-analysis 48)	Mild, transient instillation site irritation (more frequent vs. vehicle, slightly more with 0.5% vs 0.25%)	No serious adverse events reported in meta-analysis; No safety/tolerability concerns noted in ALLEVIATE	Higher rate of side effects vs. vehicle, but generally mild/transient	7
Noninfectious Anterior Uveitis (NAU)	Phase 2, Phase 3 (SOLACE)	~800 (cumulative across 9 ocular inflammation trials mentioned in 13)	Generally well-tolerated	No specific SAEs mentioned for reproxalap; Program discontinued for efficacy reasons	Did not elevate IOP unlike comparator (prednisolone) in Phase 2	7
Sjögren-Larsson Syndrome (SLS)	Phase 2 (Topical Dermal)	12 (Phase 2)	Generally well-tolerated	No significant AEs, SAEs, or discontinuations reported in Phase 2	N/A	46

This table aggregates safety information across indications, underscoring the consistent finding of good tolerability, with mild, transient instillation site effects being the predominant issue. The lack of significant safety concerns, even in long-term use and across a large patient base, represents a potential strength for reproxalap.[2]

6.5. Contraindications, Warnings, Precautions, and Drug Interactions

Specific information regarding contraindications, warnings, precautions, or drug interactions for reproxalap was not found within the provided documents.[18] DrugBank lists drug and food interactions as "Not Available".[1] A comprehensive assessment of these aspects would require access to the full Investigator's Brochure or approved product labeling, which are not included in the source materials.[10]

7. Regulatory Status and Outlook

7.1. FDA (United States)

Reproxalap's regulatory journey with the U.S. FDA has been complex, particularly for the DED indication.

• Dry Eye Disease (DED): Aldeyra submitted an initial NDA for reproxalap for the signs and symptoms of DED in November 2022.[11] This submission was based on data from five adequate and well-controlled trials covering symptoms and signs.[29] However, the FDA issued a CRL in November 2023, stating that the submission failed to demonstrate efficacy for ocular symptoms and required at least one additional adequate and well-controlled symptom trial.[11] Following discussions with the FDA, Aldeyra initiated further trials, including a dry eye chamber study focusing on symptoms.[11] After this chamber trial met its primary endpoint for ocular discomfort [2], Aldeyra resubmitted the NDA in October 2024.[11] Despite the positive new data, the FDA issued a second CRL in April 2025.[4] This second CRL reiterated the lack of demonstrated efficacy in treating ocular symptoms in adequate and well-controlled studies and mentioned potential methodological concerns (baseline imbalance) with the submitted chamber trial data.[11] Importantly, neither CRL identified safety or manufacturing issues.[4] Aldeyra plans to meet with the FDA (Type A meeting) and, contingent on positive results from ongoing DED field and chamber trials (expected Q2 2025), intends to resubmit the NDA again in mid-2025, anticipating a six-month review cycle.[2]
• Allergic Conjunctivitis (AC): Following positive results from Phase 3 trials like ALLEVIATE and INVIGORATE-2 [9], AC represents a potential indication for regulatory submission, although specific plans were not detailed in the reviewed materials.
• Sjögren-Larsson Syndrome (SLS) / Congenital Ichthyosis: Reproxalap (as ADX-102) received FDA Orphan Drug Designation for the treatment of congenital ichthyosis on April 20, 2017.[16] The FDA orphan drug database confirms designation 530116 for ADX-102 for this indication, sponsored by Aldeyra Therapeutics.[17] A Phase 3 trial (RESET, NCT03445650) has been completed [38], but the path forward for topical reproxalap in this indication is unclear, especially given the development of oral ADX-629 for SLS.[62]
• Noninfectious Anterior Uveitis (NAU): Development was terminated following the failure of the Phase 3 SOLACE trial; no regulatory submission is planned.[12]
• Expedited Programs: There is no mention in the provided documents of reproxalap receiving Fast Track or Breakthrough Therapy designation from the FDA for any indication.[41]

7.2. EMA (European Union)

Information regarding reproxalap's regulatory status with the European Medicines Agency (EMA) is sparse in the provided materials.

• Orphan Medicinal Product (OMP) Designation: No evidence was found indicating that reproxalap has received OMP designation from the European Commission for any indication, including SLS.[19] A search of the European Commission's Community Register of Orphan Medicinal Products would be needed for definitive confirmation.[72] Aldeyra has received EMA OMP designation for a different compound, ADX-2191.[75]
• Scientific Advice/CHMP Opinion: No public summaries of scientific advice provided by EMA or opinions issued by the Committee for Medicinal Products for Human Use (CHMP) regarding reproxalap were identified.[34]

The apparent lack of significant EMA engagement suggests that Aldeyra's regulatory strategy may have primarily focused on the US market, or that interactions have occurred but are not publicly documented in these sources.

7.3. Future Outlook

The immediate future for reproxalap is heavily dependent on resolving the regulatory challenges in the DED indication with the FDA. Success hinges on the ability of ongoing or future clinical trials to convincingly demonstrate statistically significant improvement in ocular symptoms in a manner acceptable to the agency.[2] A successful NDA resubmission in mid-2025 could lead to potential approval in late 2025 or early 2026, given the anticipated six-month review cycle.[2]

Allergic conjunctivitis represents a second potential indication, supported by robust Phase 3 data, which might offer an alternative or parallel path to market entry.[9] The future of topical reproxalap for SLS remains uncertain based on available information, with the company potentially prioritizing the development of the oral RASP modulator ADX-629 for this rare disease.[62] Aldeyra continues to invest in its broader RASP modulator platform, exploring other candidates like ADX-629 and ADX-248 for various systemic and retinal diseases.[2]

8. Discussion

Reproxalap stands out as a first-in-class RASP inhibitor, offering a novel, systems-based pharmacological approach to treating inflammatory conditions, particularly in ophthalmology.[5] Its mechanism, targeting upstream aldehyde mediators rather than downstream cytokines or receptors, holds theoretical appeal for broad anti-inflammatory effects.[6]

Potential advantages observed during its development include a rapid onset of action, particularly noted in controlled settings like DED chamber trials and AC allergen challenges, where effects on signs (redness) and symptoms (discomfort, itching) were seen quickly.[2] The drug has demonstrated activity across both signs and symptoms in certain contexts, suggesting a potentially broad therapeutic window.[11] Furthermore, its safety and tolerability profile appears favorable, especially when compared to potential side effects of existing therapies like the ocular irritation and dysgeusia associated with lifitegrast, or the IOP elevation risk with corticosteroids.[2] The consistent finding of mild, transient instillation site irritation as the most common AE across over 2,900 patients is a significant positive attribute.[2]

Despite these potential advantages, reproxalap faces substantial challenges. The most significant is the regulatory hurdle in DED. The repeated FDA CRLs underscore the difficulty in demonstrating consistent and statistically significant symptom improvement in adequate and well-controlled trials that satisfy regulatory requirements.[11] The divergence between positive results in controlled chamber environments and the lack of statistical significance in field trials highlights a critical translational gap.[2] Overcoming the high placebo effect and inherent variability in DED field studies remains a major obstacle for demonstrating symptom efficacy. Additionally, the failure of the Phase 3 SOLACE trial led to the discontinuation of the NAU program, indicating that the drug's efficacy may not extend equally to all types of ocular inflammation, particularly severe autoimmune conditions where standard-of-care is highly effective.[12] The lack of detailed public data on pharmacokinetics and comprehensive preclinical toxicology also limits a full assessment.[1] Finally, the unclear status of the Phase 3 RESET trial for topical reproxalap in SLS suggests potential challenges or a strategic shift within that program.[38]

In the context of the current therapeutic landscape, reproxalap's unique MoA offers a potential alternative or adjunct to existing DED treatments like artificial tears, cyclosporine, lifitegrast, topical steroids (loteprednol), varenicline nasal spray, and perfluorohexyloctane.[80] If approved, its rapid action and favorable tolerability could be key differentiators. For AC, it could provide a novel non-steroidal option alongside antihistamines, mast cell stabilizers, and NSAIDs.[82] For SLS ichthyosis, where treatment options are limited to emollients, keratolytics, and systemic retinoids with significant side effects [84], a targeted topical therapy like reproxalap (or potentially oral ADX-629) could fill a significant unmet need, reflected by its ODD.[17]

Overall, while the novel RASP inhibition mechanism is scientifically compelling and supported by preclinical data and a strong safety profile, the clinical translation into consistently demonstrable efficacy, especially for DED symptoms in registrational settings, remains the primary challenge for reproxalap.

9. Conclusion

Reproxalap (ADX-102, NS-2) is a pioneering investigational drug developed by Aldeyra Therapeutics, representing the first clinical-stage modulator of Reactive Aldehyde Species (RASP). Its unique mechanism targets upstream inflammatory mediators, offering a potentially broad and rapidly acting anti-inflammatory effect distinct from existing therapies. Clinical development has focused primarily on ocular inflammation, including dry eye disease (DED) and allergic conjunctivitis (AC), and the rare genetic disorder Sjögren-Larsson syndrome (SLS), for which it holds FDA Orphan Drug Designation for the associated congenital ichthyosis.

The drug has consistently demonstrated a favorable safety and tolerability profile across extensive clinical testing in over 2,900 patients, with mild, transient instillation site irritation being the most common adverse event. Efficacy has been clearly demonstrated in Phase 3 trials for AC using controlled allergen challenge models. However, the development path for DED has been hindered by significant regulatory setbacks, with two FDA Complete Response Letters citing insufficient demonstration of efficacy on ocular symptoms in adequate and well-controlled trials, despite positive results in controlled chamber studies and for ocular signs. Development for noninfectious anterior uveitis was discontinued after a Phase 3 trial failure. The status of the topical formulation for SLS is uncertain following completion of a Phase 3 trial, with focus potentially shifting to an oral RASP modulator.

In conclusion, reproxalap's novel mechanism and strong safety profile remain promising attributes. Its future hinges critically on Aldeyra's ability to generate convincing symptom efficacy data for DED that satisfies FDA requirements, with ongoing trials and a planned NDA resubmission in mid-2025 being pivotal. Success in the AC indication may provide an alternative route to market. Reproxalap's journey highlights both the potential of targeting RASP and the significant challenges in translating novel mechanisms into registrational endpoints, particularly for complex conditions like DED.

10. References

[1]

Works cited

1. Reproxalap: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed May 8, 2025, https://go.drugbank.com/drugs/DB16688
2. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-achieves-primary-endpoint-phase-3-dry-eye-0
3. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission, accessed May 8, 2025, https://ir.aldeyra.com/node/12781/pdf
4. Aldeyra Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of, accessed May 8, 2025, https://ir.aldeyra.com/node/12711/pdf
5. What is Reproxalap used for? - Patsnap Synapse, accessed May 8, 2025, https://synapse.patsnap.com/article/what-is-reproxalap-used-for
6. FDA does not approve resubmitted new drug application for reproxalap - Healio, accessed May 8, 2025, https://www.healio.com/news/ophthalmology/20250403/fda-does-not-approve-resubmitted-new-drug-application-for-reproxalap
7. Reproxalap for the Treatment of Dry Eye Disease - touchOPHTHALMOLOGY, accessed May 8, 2025, https://touchophthalmology.com/ocular-surface-disease/journal-articles/reproxalap-for-the-treatment-of-dry-eye-disease/
8. FDA Denies Approval for Reproxalap for Dry Eye Disease - MedCentral, accessed May 8, 2025, https://www.medcentral.com/ophthalmology/fda-decision-on-reproxalap-for-dry-eye-disease
9. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis - PMC, accessed May 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10725700/
10. Reproxalap for the Treatment of Dry Eye Disease - SciSpace, accessed May 8, 2025, https://scispace.com/pdf/reproxalap-for-the-treatment-of-dry-eye-disease-2smz9riz.pdf
11. Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food-0
12. Aldeyra's Reproxalap Falls Short in Anterior Uveitis Trial - BioSpace, accessed May 8, 2025, https://www.biospace.com/aldeyra-therapeutics-reproxalap-fails-eye-disease-trial
13. Aldeyra Therapeutics Announces Results from the SOLACE Trial in ..., accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-results-solace-trial
14. Reproxalap API Suppliers - Find All GMP Manufacturers - Pharmaoffer.com, accessed May 8, 2025, https://pharmaoffer.com/api-excipient-supplier/reproxalap
15. REPROXALAP - Inxight Drugs, accessed May 8, 2025, https://drugs.ncats.io/drug/F0GIZ22IJH
16. Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-inc-receives-orphan-drug-designation-us
17. REPROXALAP - precisionFDA, accessed May 8, 2025, https://precision.fda.gov/ginas/app/ui/substances/c03bc280-40eb-49fd-bb3a-7061e9659b59
18. Reproxalap: What is it and is it FDA approved? - Drugs.com, accessed May 8, 2025, https://www.drugs.com/history/reproxalap.html
19. reproxalap for the potential treatment of dry eye disease - Public now, accessed May 8, 2025, https://docs.publicnow.com/viewDoc.aspx?filename=135856\EXT\A2A7DEC9A1B7E79766BF6A00116F8536579F1F09_56FC7E5497402C552E9F505279F9C6B48B2BA9EB.PDF
20. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial - PubMed, accessed May 8, 2025, https://pubmed.ncbi.nlm.nih.gov/33945820/
21. Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-top-line-results-12
22. FDA issues Complete Response Letter to Aldeyra Therapeutics for resubmitted New Drug Application of reproxalap - Ophthalmology Times, accessed May 8, 2025, https://www.ophthalmologytimes.com/view/fda-issues-complete-response-letter-to-aldeyra-therapeutics-for-resubmitted-new-drug-application-of-reproxalap
23. Reproxalap (ADX-102; NS-2) | CAS 916056-79-6 - AbMole BioScience, accessed May 8, 2025, https://www.abmole.com/products/reproxalap.html
24. Reproxalap | CAS NO.:916056-79-6 - GlpBio, accessed May 8, 2025, https://www.glpbio.com/reproxalap.html
25. Reproxalap (ADX-102) | Aldehyde Inhibitor - MedchemExpress.com, accessed May 8, 2025, https://www.medchemexpress.com/reproxalap.html
26. ADX-102 (Reproxalap;NS-2) - Biorbyt, accessed May 8, 2025, https://www.biorbyt.com/adx-102-reproxalapns-2-orb746442.html
27. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease - PubMed Central, accessed May 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8106247/
28. 2022 Pharma Update: New Anterior Segment Treatments - Eyes On Eyecare, accessed May 8, 2025, https://eyesoneyecare.com/resources/2022-pharma-update-new-anterior-segment-treatments/
29. Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-submits-new-drug-application-us-food-and
30. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap, accessed May 8, 2025, https://ir.aldeyra.com/node/12526/pdf
31. Reproxalap - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 8, 2025, https://synapse.patsnap.com/drug/a64e84a93cd84dce889db33830cb2194
32. Clinical Trial Protocol: ADX-102-DED-012 - ClinicalTrials.gov, accessed May 8, 2025, https://cdn.clinicaltrials.gov/large-docs/63/NCT03879863/Prot_000.pdf
33. Clinical Trial Protocol: ADX-102-DED-013 - ClinicalTrials.gov, accessed May 8, 2025, https://cdn.clinicaltrials.gov/large-docs/42/NCT03916042/Prot_000.pdf
34. Aldeyra Therapeutics Announces Positive Results from Dry Eye Disease Phase 2a Clinical Trial, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-dry-eye-disease
35. Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-presents-noninfectious-anterior-uveitis-0
36. Clinical Trial Protocol: ADX-102-DED-009 - ClinicalTrials.gov, accessed May 8, 2025, https://cdn.clinicaltrials.gov/large-docs/15/NCT03404115/Prot_000.pdf
37. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease - PMC, accessed May 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8473572/
38. Reproxalap ( DrugBank - DDrare: Database of Drug Development for Rare Diseases, accessed May 8, 2025, https://ddrare.nibn.go.jp/ddrare_Mar2023/ddrare_Mar2022/cgi-bin/drug_who_e.cgi?query=Reproxalap&disease_id=160
39. Adx-102 1% topical dermal cream (reproxalap) - DDrare: Database ..., accessed May 8, 2025, https://ddrare.nibn.go.jp/cgi-bin/drug_who_e.cgi?query=adx-102%201%25%20topical%20dermal%20cream%20%28reproxalap%29&disease_id=160
40. Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-first-patient-enrolled-sjogren-0
41. Aldeyra Therapeutics achieves primary endpoint in phase 3 DED chamber trial of reproxalap and plans NDA resubmission - Glance by Eyes On Eyecare, accessed May 8, 2025, https://glance.eyesoneyecare.com/press-releases/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-ded-chamber-trial-of-reproxalap-and-plans-nda-resubmission/
42. Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-presents-noninfectious-anterior-uveitis
43. Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-launches-aldeyra-registry-patients-sjogren
44. Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease - Drugs.com, accessed May 8, 2025, https://www.drugs.com/nda/reproxalap_250403.html
45. Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease - BioSpace, accessed May 8, 2025, https://www.biospace.com/press-releases/aldeyra-therapeutics-receives-complete-response-letter-from-the-u-s-food-and-drug-administration-for-the-reproxalap-new-drug-application-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease
46. Aldeyra Therapeutics Announces Positive Results from a Randomized, Double-Blind, Vehicle-Controlled Clinical Trial of Topical Dermatologic NS2 in Patients With Sjögren-Larsson Syndrome, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-randomized
47. Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial - PR Newswire, accessed May 8, 2025, https://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-first-patient-enrolled-in-sjogren-larsson-syndrome-pivotal-phase-3-clinical-trial-300685365.html
48. Reproxalap in patients with seasonal allergic conjunctivitis: a systematic review and meta-analysis - PMC, accessed May 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12037956/
49. (PDF) Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure - ResearchGate, accessed May 8, 2025, https://www.researchgate.net/publication/357541592_Reproxalap_Improves_Signs_and_Symptoms_of_Allergic_Conjunctivitis_in_an_Allergen_Chamber_A_Real-World_Model_of_Allergen_Exposure
50. Reproxalap ophthalmic dosing, indications, interactions, adverse effects, and more, accessed May 8, 2025, https://reference.medscape.com/drug/reproxalap-ophthalmic-4000363
51. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission | Morningstar, accessed May 8, 2025, https://www.morningstar.com/news/business-wire/20250506374075/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-chamber-trial-of-reproxalap-and-plans-nda-resubmission
52. Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting, accessed May 8, 2025, https://ir.aldeyra.com/node/11746/pdf
53. Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease, accessed May 8, 2025, https://www.ajmc.com/view/reproxalap-approved-by-fda-for-use-in-dry-eye-disease
54. Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap, accessed May 8, 2025, http://www.ophthalmologytimes.com/view/aldeyra-therapeutics-hits-primary-end-point-in-1-of-2-phase-3-trials-for-reproxalap
55. Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission - Business Wire, accessed May 8, 2025, https://www.businesswire.com/news/home/20250506374075/en/Aldeyra-Therapeutics-Achieves-Primary-Endpoint-in-Phase-3-Dry-Eye-Disease-Chamber-Trial-of-Reproxalap-and-Plans-NDA-Resubmission
56. Phase II clinical trial data of biopharma companies in 2023 - BioWorld, accessed May 8, 2025, https://www.bioworld.com/content/phase2-data-2023
57. Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-schedules-conference-call-and-webcast-9
58. Dry Eye Completed Phase 2 Trials for Reproxalap (DB16688) | DrugBank Online, accessed May 8, 2025, https://go.drugbank.com/indications/DBCOND0033943/clinical_trials/DB16688?phase=2&status=completed
59. US FDA issues second Complete Response Letter for dry eye drug reproxalap (Aldeyra Therapeutics) - Ophthalmology Times Europe, accessed May 8, 2025, https://europe.ophthalmologytimes.com/view/us-fda-issues-second-complete-response-letter-for-dry-eye-drug-reproxalap-aldeyra-therapeutics-
60. Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights - SEC.gov, accessed May 8, 2025, https://www.sec.gov/Archives/edgar/data/1341235/000115752323000419/a53358602ex99_1.htm
61. Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap, accessed May 8, 2025, https://www.ophthalmologytimes.com/view/aldeyra-therapeutics-hits-primary-end-point-in-1-of-2-phase-3-trials-for-reproxalap
62. Topline Data Release and NDA Resubmission Plan, accessed May 8, 2025, https://ir.aldeyra.com/static-files/6e64d611-ab05-4f31-abd1-2400d35324ae
63. ADX-629 Therapy for Sjogren-Larsson Syndrome - ClinicalTrials.Veeva, accessed May 8, 2025, https://ctv.veeva.com/study/adx-629-therapy-for-sjogren-larsson-syndrome
64. Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-advancement-new-rasp-modulators
65. Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease, accessed May 8, 2025, http://www.ajmc.com/view/reproxalap-approved-by-fda-for-use-in-dry-eye-disease
66. Innovating Transformative Therapies - Investor Relations | Aldeyra Therapeutics, Inc., accessed May 8, 2025, https://ir.aldeyra.com/static-files/0e075f52-55e5-4894-bee5-a2ab56db2f1e
67. Innovative Approaches to Regulating Immune Response - Investor Relations | Aldeyra Therapeutics, Inc., accessed May 8, 2025, https://ir.aldeyra.com/static-files/7bdc51bf-92ab-4f06-ad10-c9257ea0acc7
68. Reproxalap for the Potential Treatment of Dry Eye Disease: Regulatory Update - Investor Relations | Aldeyra Therapeutics, Inc., accessed May 8, 2025, https://ir.aldeyra.com/static-files/afff3883-6b2d-4aa7-8a28-0df0fd244b2f
69. Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView, accessed May 8, 2025, https://www.tradingview.com/news/tradingview:e1017d3f08a09:0-aldeyra-therapeutics-inc-sec-10-k-report/
70. Lacrivera launches dry eye line - Optometry Times, accessed May 8, 2025, https://www.optometrytimes.com/view/lacrivera-launches-dry-eye-line
71. Sjögren-Larsson syndrome - Orphanet, accessed May 8, 2025, https://www.orpha.net/en/disease/detail/816
72. Orphan designation: Overview | European Medicines Agency (EMA), accessed May 8, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
73. Reproxalap - Uses, DMF, Dossier, Manufacturer, Supplier, Licensing, Distributer, Prices, News, GMP - PharmaCompass.com, accessed May 8, 2025, https://www.pharmacompass.com/active-pharmaceutical-ingredients/reproxalap
74. RxOutlook. The report - OptumRx | Healthcare professionals portal, accessed May 8, 2025, https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/news/outlook/ORX6204_191121_B2B-NEWSLETTER_RxOutlook_2019Q4_FINAL.pdf
75. Aldeyra Therapeutics Receives Orphan Medicinal Product Designation from the European Commission for ADX-2191 Retinal Disease Program, accessed May 8, 2025, https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-orphan-medicinal-product
76. accessed January 1, 1970, https://www.ema.europa.eu/en/medicines/ema_group_types/ema_orphan/orphan-designations-reports
77. EMA - European Union, accessed May 8, 2025, https://www.ema.europa.eu/en
78. Scientific advice and protocol assistance | European Medicines Agency (EMA), accessed May 8, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-advice-protocol-assistance
79. accessed January 1, 1970, https://www.ema.europa.eu/en/medicines/search_authorisations
80. Overview of Dry Eye Disease for Primary Care Physicians - MDPI, accessed May 8, 2025, https://www.mdpi.com/1648-9144/61/3/460
81. Dry Eye Syndrome PPP 2023 - American Academy of Ophthalmology, accessed May 8, 2025, https://www.aao.org/education/preferred-practice-pattern/dry-eye-syndrome-ppp-2023
82. Progress Towards a Consensus on Conjunctivitis - Review of Optometry, accessed May 8, 2025, https://www.reviewofoptometry.com/article/progress-towards-a-consensus-on-conjunctivitis
83. Anti-inflammatories in Ocular Allergy Treatment - Review of Optometry, accessed May 8, 2025, https://www.reviewofoptometry.com/article/anti-inflammatories-in-ocular-allergy-treatment
84. Sjogren-Larsson Syndrome: Mechanisms and Management - PMC - PubMed Central, accessed May 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6954685/
85. Genetics of Sjogren-Larsson Syndrome Treatment & Management - Medscape Reference, accessed May 8, 2025, https://emedicine.medscape.com/article/949023-treatment
86. Get Ahead of the Game - Review of Optometry, accessed May 8, 2025, https://www.reviewofoptometry.com/article/get-ahead-of-the-game
87. The Toolbox for Noninfectious Uveitis - Review of Ophthalmology, accessed May 8, 2025, https://www.reviewofophthalmology.com/article/the-toolbox-for-noninfectious-uveitis
88. New Pharmacological Strategies for the Treatment of Non-Infectious Uveitis. A Minireview, accessed May 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7250389/
89. CLINICAL STUDY PROTOCOL - ClinicalTrials.gov, accessed May 8, 2025, https://cdn.clinicaltrials.gov/large-docs/04/NCT05487404/Prot_000.pdf
90. Aldeyra Therapeutics, Inc. - ADX-629-CC-001 - ClinicalTrials.gov, accessed May 8, 2025, https://cdn.clinicaltrials.gov/large-docs/92/NCT05392192/SAP_001.pdf
91. Advanced Filter - DrugBank, accessed May 8, 2025, https://go.drugbank.com/unearth/q?button=&c=_score&d=down&page=437&query=mixture+of+polynuclear+iron+iii+oxyhydroxide+sucralose+and+starch&searcher=drugs
92. Orphan Designations/Approvals - Drug Database, accessed May 8, 2025, https://drugdatabase.info/orphan-designations-approvals/
93. Search Orphan Drug Designations and Approvals - FDA, accessed May 8, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=540116
94. accessed January 1, 1970, https://clinicaltrials.gov/search?term=Reproxalap%20OR%20ADX-102%20OR%20NS-2&aggFilters=phase:2,phase:3,studyType:int
95. Search Orphan Drug Designations and Approvals, accessed May 8, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/
96. ClinicalTrials.gov: Home, accessed May 8, 2025, https://www.clinicaltrials.gov
97. Search Orphan Drug Designations and Approvals, accessed May 8, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
98. accessed January 1, 1970, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=586417
99. accessed January 1, 1970, https://www.biospace.com/article/aldeyra-s-reproxalap-fails-eye-disease-trial/
100. accessed January 1, 1970, https://clinicaltrials.gov/study/NCT03445650